American Journal of Physiology-Cell Physiology · 2006 · 12 citations · 25 references
Life SciencesCell BiologyMolecular BiologyApoptosisCell SignalingSignal TransductionEndothelial ActivationEndothelial DysfunctionReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsIntracellular Signaling PathwaysJak Inhibitor TherapyJak InhibitorsJak-stat Pathway AntagonismJak-stat Signaling PathwayJanus Kinase-stat Signaling ActivationProtectionProtective Treatments
Inhibition of the JAK2/STAT pathway has been implicated recently in cytoprotective mechanisms in both vascular smooth muscle cells and astrocytes. The advent of JAK2-specific inhibitors provides a practical tool for the study of this pathway in different cellular types. An interest in finding methods to improve endothelial cell (EC) resistance to injury led us to examine the effect of JAK2/STAT inhibition on EC protection. Furthermore, the signaling pathways involved in JAK2/STAT inhibition-related actions were examined. Our results reveal, for the first time, that blockade of JAK2 with the tyrosine kinase inhibitor AG490 strongly protects cultured EC against cell detachment-dependent death and serum deprivation and increases reseeding efficiency. Confirmation of the specificity of the effects of JAK2 inhibition was attained by finding protective effects on transfection with a dominant negative JAK2. Furthermore, AG490 blocked serum deprivation-induced phosphorylation of JAK2. In terms of mechanism, treatment with AG490 induces several relevant responses, both in monolayer and detached cells. These mechanisms include the following: 1) Increase and nuclear translocation of the active, dephosphorylated form of beta-catenin. In functional terms, this translocation is transcriptionally active, and its protective effect is further supported by the stimulation of EC cytoprotection by transfectionally induced excess of beta-catenin. 2) Increase of platelet endothelial cell adhesion molecule (PECAM)/CD31 levels. 3) Increase in total and phosphorylated AKT. 4) Increase in phosphorylated glycogen synthase kinase (GSK)3alpha/beta. The present findings imply potential practical applications of JAK2 inhibition on EC. These applications affect not only EC in the monolayer but also circulating detached cells and involve mechanistic interactions not previously described.
25
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Naftaly Meydan, T Grunberger, Harjit Dadi et al. · Nature · 1996 · 912 citations
Keith Orford, Caroline C. Orford, Stephen W. Byers · The Journal of Cell Biology · 1999 · 276 citations · Full text
JAK/STAT Signaling Is Associated With Cardiac Dysfunction During Ischemia and Reperfusion
Eduardo Mascareno, M. E. El-Shafei, Nilanjana Maulik et al. · Circulation · 2001 · 201 citations · Full text
Medicine, Cardiology, Pharmacology +15